Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults
Authors:
Open Access
- 23 August 2023
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7 (6) , 102181
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 11 references indexed in Scilit:
- A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeysJournal of Thrombosis and Haemostasis, 2022
- A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A miceBlood, 2021
- Hemophilic arthropathy: Current knowledge and future perspectivesJournal of Thrombosis and Haemostasis, 2021
- WFH Guidelines for the Management of Hemophilia, 3rd editionHaemophilia, 2020
- Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII ProductsJournal of Managed Care & Specialty Pharmacy, 2020
- Hemophilia A and B: molecular and clinical similarities and differencesHaematologica, 2019
- New therapies for hemophiliaBlood, 2019
- Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitorsBlood Advances, 2017
- A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjectsBlood, 2016
- Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in RatsPharmaceutical Research, 2011